Merck discontinues late-stage trial of vibostolimab-Keytruda combo for severe skin cancer due to insufficient efficacy.
Merck has discontinued testing a combination of an experimental antibody-based drug, vibostolimab, and its blockbuster immunotherapy, Keytruda, for patients with severe skin cancer in a late-stage study. The decision follows an analysis showing that the trial is unlikely to achieve a statistically significant improvement in recurrence-free survival, the main goal. Merck will unblind the study and recommend patients receiving the combination treatment be offered Keytruda monotherapy.
May 13, 2024
9 Articles